Format

Send to

Choose Destination
Int J Oncol. 1997 Mar;10(3):521-8.

p53 status and prognosis in stage I-IIIa non-small cell lung cancer.

Author information

1
KINKI UNIV,SCH MED,DEPT INTERNAL MED 4,OSAKA,OSAKA 589,JAPAN. GIFU UNIV,SCH MED,DEPT INTERNAL MED 2,GIFU 500,JAPAN. OSAKA PREFECTURE HABIKINO HOSP,DEPT INTERNAL MED,HABIKINO,OSAKA 583,JAPAN. OSAKA PREFECTURE HABIKINO HOSP,DEPT SURG,HABIKINO,OSAKA 583,JAPAN. OSAKA PREFECTURE HABIKINO HOSP,DEPT PATHOL,HABIKINO,OSAKA 583,JAPAN.

Abstract

To investigate the role of p53 abnormalities in predicting the survival of patients with non-small cell lung cancer (NSCLC), polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) and immunohistochemical analyses were performed on 74 and 67 tumor samples, respectively, from patients with pathological stage I-IIIa NSCLC. An abnormally migrating SSCP band was observed in 21 of 74 (28%) tumor specimens. DNA sequence analysis revealed 23 intragenic mutations including 3 small deletions and 20 point mutations. Immunohistochemical analysis using the DO-7 monoclonal antibody showed abnormal expression of p53 in 27 of 67 (40%) patients. The concordance rate between immunohistochemical and PCRSSCP analyses was 73% (49/67) in this study. Univariate and multivariate analyses demonstrated that abnormal expression of p53 may be associated with prolonged survival (p=0.0997 and 0.0099, respectively). In contrast, no relationship was observed between p53 mutation and overall survival (0.6968). These results suggest that p53 status and the survival outcome changes between immunohistochemical and mutational analyses in stage I-IIIa NSCLC.

PMID:
21533407
DOI:
10.3892/ijo.10.3.521

Supplemental Content

Full text links

Icon for Spandidos Publications
Loading ...
Support Center